U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07670962) titled 'Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy' on June 22.
Brief Summary: The purpose of this observational study is to learn if a specialized blood test can help predict whether advanced ovarian cancer will return after a patient's initial treatments are finished.
Researchers are inviting women who have been diagnosed with stage III or IV epithelial ovarian cancer and have recently completed their first-line treatments, which include surgery and platinum-based chemotherapy.
The study focuses on "circulating tumor DNA" (ctDNA), which are tiny fragments of genetic material that ca...